Letter ·
NAMD Submits Comments on Medicaid Drug Rebate Program Proposed Rule
On July 25, NAMD submitted comments on CMS’s proposed rule on the Medicaid Drug Rebate Program (MDRP).
Author
- NAMD Staff
Focus Areas
On July 25, NAMD submitted comments on CMS’s proposed rule on the Medicaid Drug Rebate Program (MDRP). This proposed rule would create a drug price verification survey, under which manufacturers would be required to provide detailed data to CMS on certain high-cost drugs, along with definitional and operational changes to the MDRP.
NAMD appreciates CMS’s focus on high-cost drugs and strongly supports many of the provisions in this rule, including the proposed drug price verification survey, dispute time limits, and pharmacy benefit manager spread pricing policies. Medicaid Directors do, however, report concerns in response to CMS’s request for information on the impact of requiring a patient’s diagnosis be on a prescription as a condition of receiving federal match.
Related resources
NAMD Comments on Senate Finance Committee’s Generic Drug Legislation
The legislation would exclude most generic drugs from the Medicaid Drug Rebate Program's inflationary rebates.
Prescription Drug Spending: What’s Coming Next for Medicaid and How Can States Prepare?
Experts at the NAMD Fall Conference discussed challenges with high-cost drugs.
Stay Informed
Drop us your email and we’ll keep you up-to-date on Medicaid issues.